| Summary of Revenue Significant Expenses and Net Loss for Segment |
The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2025 |
|
|
2024 |
|
Collaboration revenue |
|
$ |
398 |
|
|
$ |
1,534 |
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
Clinical related costs |
|
|
2,920 |
|
|
|
15,156 |
|
Employee related costs |
|
|
10,557 |
|
|
|
22,828 |
|
Product development and manufacturing costs |
|
|
818 |
|
|
|
3,304 |
|
Facilities, support costs and depreciation |
|
|
10,718 |
|
|
|
13,579 |
|
Professional, consulting and public company costs |
|
|
4,938 |
|
|
|
7,400 |
|
Impairment of property and equipment |
|
|
— |
|
|
|
1,883 |
|
Impairment of right-of-use assets |
|
|
— |
|
|
|
22,836 |
|
Restructuring and other related charges |
|
|
1,469 |
|
|
|
10,896 |
|
Total operating expenses |
|
|
31,420 |
|
|
|
97,882 |
|
Loss from operations |
|
|
(31,022 |
) |
|
|
(96,348 |
) |
Other income: |
|
|
|
|
|
|
Interest income |
|
|
1,133 |
|
|
|
2,952 |
|
Other income |
|
|
981 |
|
|
|
— |
|
Total other income |
|
|
2,114 |
|
|
|
2,952 |
|
Loss before income tax expense |
|
|
(28,908 |
) |
|
|
(93,396 |
) |
Income tax expense |
|
|
(11 |
) |
|
|
(39 |
) |
Net loss |
|
$ |
(28,919 |
) |
|
$ |
(93,435 |
) |
|